期刊
JOURNAL OF INFECTIOUS DISEASES
卷 218, 期 -, 页码 S662-S665出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiy235
关键词
filovirus; Marburg virus; hamster model; monoclonal mouse antibody; treatment
资金
- Division of Intramural Research, NIAID, NIH
- KAKENHI of the Japan Society for the Promotion of Science [16H02627, 25892002]
- Japanese Agency for Medical Research and Development [JP17fk0108101]
- Grants-in-Aid for Scientific Research [25892002, 16H02627] Funding Source: KAKEN
Marburg virus (MARV), family Filoviridae, causes Marburg hemorrhagic fever (MHF) in humans and nonhuman primates with case fatality rates of up to 90%. There is no approved therapeutic for MHF, yet several experimental approaches have been evaluated in preclinical studies including small interfering RNA and monoclonal antibody (mAb) treatment. In this study we attempted to improve the therapeutic efficacy of the neutralizing mAb M4 by combining treatment with 1 or 2 of blocking but nonneutralizing mAbs 126-15 and 127-8. We found that single-dose treatment early after infection with the neutralizing mAb M4 or any of the mAb combinations resulted in similar protection in the MARV hamster model. However, a single-dose treatment with the cocktail of all 3 mAbs provided the best protection in delayed treatment, with 67%-100% of the animals surviving a lethal challenge depending on the time of treatment. This study identified a new promising mAb cocktail as a therapeutic option for MHF.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据